Understanding the genetics of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Dissecting the Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
This study is trying to see how certain genes might affect people with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and their treatment, by comparing genetic information from CIDP patients to healthy individuals.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 3500 (estimated) |
| Sex | All |
| Sponsor | Istituto Clinico Humanitas Academic / other |
| Locations | 1 site (Rozzano) |
| Trial ID | NCT06325878 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the genetic factors associated with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) by conducting a genome-wide association study (GWAS) on a large cohort of CIDP patients and healthy controls. Researchers will analyze over 700,000 single nucleotide polymorphisms (SNPs) from approximately 1,000 CIDP patients and compare these with data from 3,500 healthy controls. The study will explore how specific genetic variants may influence the clinical presentation, severity, and treatment responses of CIDP, including associations with other autoimmune conditions. The findings could enhance understanding of CIDP's genetic underpinnings and improve patient management.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with a documented diagnosis of CIDP according to established criteria.
Not a fit: Patients with alternative diagnoses for their neuropathy or without available nerve conduction studies will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better-targeted therapies and personalized treatment strategies for patients with CIDP.
How similar studies have performed: Previous studies using GWAS approaches have shown promise in identifying genetic factors in other autoimmune diseases, suggesting potential for success in this novel investigation of CIDP.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: - Subject with a documented diagnosis of according to the EAN/PNS criteria Exclusion Criteria: * Subject with an alternative diagnosis for the neuropathy * Subject without available nerve conduction studies or documented diagnosis of CIDP
Where this trial is running
Rozzano
- IRCCS Istituto Clinico Humanitas — Rozzano, Italy (Recruiting)
Study contacts
- Principal investigator: Pietro Emiliano Doneddu, MD — Humanitas Research Institute
- Study coordinator: Pietro Emiliano Emiliano Doneddu, MD
- Email: pietro.doneddu@hunimed.eu
- Phone: 00390282247761
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.